16th ICASA Addis Ababa, Ethiopia 4th – 8th December 2011 Roadmap of HIV/TB Sessions

SUNDAY, 4 DECEMBER 2011

Satellite Symposia: SUSAT05 Time: 10:00 - 11:30 Venue: B3 Shalla Overcoming Inaction in Workplace HIV and TB Control – Integration into Occupational Safety and Health (OSH) as a Path to Greater Ownership and Sustainability

MONDAY, 5 DECEMBER 2011

Oral Abstract Session: MOAC02 Time: 10:45 - 12:15 Venue: A5 Omo HIV Detection Methods and Surveillance

10:45 MOAC0201 Strengthening Laboratory TB Diagnostic Capacity of Peripheral Laboratories in East Central Uganda - A Key Contributing Factor to Increasing TB Case Detection Rate, *Silver Mashate, Uganda*

Oral Poster Discussion: MOPDB02 Time: 12:30 – 13:30 Venue: B5 Nyala Challenges with TB/HIV Co-Management in Africa

12:30 MOPDB0201 Burden, Challenges and Associated Factors of TB/HIV Co-Infection in Pregnant Nigerians, *Oliver Ezechi, Nigeria*

12:40 MOPDB0202 Devenir des Patients Co-Infectés TB/VIH Perdus de Vue à Dakar, Sénégal, Cossi Angelo Attinsounon, Senegal

12:50 MOPDB0203 Fluorescence Microscopy Shortens Time to Mycobacterium Tuberculosis Diagnosis and Reduces Laboratory Work Loads, *Girmachew Fantaye, Ethiopia*

13:00 MOPDB0204 Reduced Time to Initiation of Anti-Retroviral Therapy at Integrated TB/HIV Sites Compared to Non-Integrated Sites: A Retrospective Cohort Study in Rural Kenya, *Mercy Jebet Seii, Kenya*

13:10 MOPDB0205 A National Approach of the Intensified TB Screening in HIV Infected People in Rwanda, *Francois Uwinkindi, Rwanda*

Oral Abstract Session: MOAB02 Time: 14:00 – 15:30 Venue: A2 Axum The Management of HIV/TB – An Ongoing Challenge

14:00 MOAB0201 Scaling up TB/HIV Services - the Experience of Southern Province, Zambia, *Cuthbert Kanene, Zambia*

14:15 MOAB0202 On TB treatment Survival of HIV Positive TB Patients on Short Course Chemotherapy in Southern Ethiopia: A Retrospective Cohort Study, *Debebe Shaweno, Ethiopia*

14:30 MOAB0203 Associated Factors with Conversion or Reversion of Quantiferon TB Gold after 12 Months Follow Up, with or without ART, INH Prophylaxis or not, in HIV Infected Patients in Sub Saharan Africa, *Christine Danel, Cote d'Ivoire*

14:45 MOAB0204 HIV-MDRTB Treatment in Ethiopia: A Successful Hospital and Community-based Treatment Model since 2009, *Daniel Meressa, Ethiopia*

15:00 MOAB0205 Efficacy as Well as Safety of Immediate Versus Deferred Initiation of HAART in TB/HIV Co-Infected Patients with CD4 Counts Less than 200 Cells/mm3, *Wondwossen Degu, Ethiopia*

Oral Abstract Session: MOAC04	Time: 14:00 - 15:30	Venue: A5 Omo
HIV/AIDS and Co-Infections		

Abstracts MOAC0401; MOAC0403; MOAC0404

Oral Abstract Session: MOAC05 Time: 14:00 - 15:30 Venue: A6, Simien Health Systems Strengthening and HIV Integration MOAC0502

Oral Abstract Session: MOAC06 Time: 14:00 - 15:30 Monitoring and Evaluation of HIV Programmes MOAC0604 Venue: B1Awash

Be part of the global body that coordinates the response to the dual TB and HIV epidemic, advice on policies and programmes to tackle the HIV associated TB problem. Join the Global TB/HIV Working Group of the Stop TB Partnership. If interested send an email to <u>tbhiv@who.int</u>, visit <u>http://www.stoptb.org/wg/tb hiv/</u>, like the TB/HIV Working Group facebook page and follow us on twitter @HIVTB. The Stop TB Department of WHO manages the Secretariat of the Working Group.



TUESDAY, 6 DECEMBER 2011

Oral Abstract Session: TUAB07 Time: 14:00 - 15:30 Venue: B2 Abiyata Ineffective PMTCT - Detecting and Treating HIV Positive Children TUAB0704

Oral Abstract Session: TUAC12 Time: 15:45 – 17:15 Venue: B1 Awash HIV Prevention in Key Populations TUAC1203

Non Abstract Driven: TULNADS17 Time: 15:45 – 17:15 Venue: A7 Lalibela Public-Private Partnership in Response to HIV, TB, Malaria and STIs 16:20 Private Sector Health Care Delivery in the Scale and Sustainability of a National Response to HIV, TB, Malaria and STI, *Tesfai Gebre-Kidan, Ethiopia*

Satellite Symposia: TUSAT35Time: 17:30 - 19:00Venue: B5 NyalaCommunity Based and Integrated TB and HIV Services Through theEffective Engagement of Nongovernmental Organizations: A SatelliteSymposium organized by the Stop TB Department of WHO to consult on the developmentof operational guidance for NGO involvement in community-based TB activities

WEDNESDAY, 7 DECEMBER 2011

Non Abstract driven: WESNADS25 Time: 14:00 – 15:30 Venue: A4 Tekeze Challenges in Tuberculosis and HIV Co-Infection

14:05 The Global Burden of TB/HIV and MDR with a Focus on Africa, Haileyesus Getahun, WHO

14:20 State of the Art: Treating TB/HIV and MDR/HIV, Rocio Hurtado, United States

14:30 : Latest Results from Ethiopia on the Timing of TB/ART, Wondwossen Amogne, Ethiopia

14:45 Initiation of MDR and MDR-HIV Care in Ethiopia, Daniel Meeresa, Ethiopia

15:00 Insights from the CAMELIA: The immune response to HIV/TB co-infection , Anne Goldfeld, US

Oral Abstract Session: WEA05 Time: 14:00 - 15:30 Venue: A3 Fasiledes Vulnerable Populations

WEAE0502

Oral Abstract Session: WEAA04 Time: 14:00 - 15:30 Venue: B3 Shalla Immunology of HIV, Pathogeniesis (HIV 1/2), Host Genetics and HIV Infections WEAA0403

Time: 14:00 - 15:30

Oral Abstract Session: WEAE06 Financing HIV Responses WEAE0605

Oral Abstract Session: WEAE10 Time: 15:45 - 17:15 Venue: A5 Omo Collaboration and Partnerships in HIV WEAE1001

Oral Abstract Session: WEAA06 Time: 15:45 - 17:15 Venue: B4 Walia HIV Transmission and Early Infections, and Co-Infections Abstracts WEAA0601; WEAA0602; WEAA0603; WEAA0605

 Satellite Symposia: WESAT51
 Time: 17:30 - 18:30
 Venue: B7 Sof Omer

 HIV Integration: A Health Systems Perspective
 TB and HIV services integration: global experiences and challenges. Haileyesus Getahun, WHO

Community Dialogue Session Time: 17:30 – 18:30 Venue: C1 Harar Jugol The Community Response to the HIV/TB Co-infection in Africa

THURSDAY, 8 DECEMBER 2011

Plenary Session: THPL05

Time: 08:40 – 10:15 Venue: A1 Abay

09:25 Achieving Universal Access to HIV Treatment for TB Patients: Science and Politics, *Diane V. Havlir, United States*

Late Breaker Session: THLB02 Time: 10:45 - 12:15 Venue: A5 Omo Immunological and Molecular Markers in HIV and Co-Infections

10:55 THLB0202 The Dynamics of HIV RNA, CD4+ Count and Mycobacterium tuberculosis (Mtb) Antigen Specific Cytokines in TB/HIV Patients Following Successful Tuberculosis (TB) Treatment, *Desta Kassa Misgena, Ethiopia*

11:05 THLB0203 Immunological and Clinical Outcomes of HIV-Positive Adolescents on ART, Gedeon Nkiko, Rwanda

Late Breaker Session: THLB05 Time: 10:45- 12:15 Financing and Capacity Building in HIV Programming THLB0504

Late Breaker Session: THLB06 Time: 10:45 – 12:15 Improving Access to Care: Application of Novel Tools THLB0602

Venue: B3 Shalla

Venue: B2 Abiyata

Venue: A5 Omo